Mölnlycke, a world-leading medical solutions company, will unveil the Power of Gentle Campaign at the 2024 annual meeting of the American Burn Association (ABA).

During the American Burn Association’s annual meeting in Chicago, Illinois, from April 9th to 12th, Mölnlycke will showcase "The Power of Gentle" campaign, aimed at enhancing the patient experience through its advanced wound care products for burns.

“At Mölnlycke, we believe that healing goes beyond surviving -- it’s about returning to daily life,” said Dwight Thomas, Vice President Mölnlycke Wound Care US “Burn survivors need the best possible treatment that reduces additional trauma in the gentlest way. Our holistic approach to burn treatment begins on the first day of the injury and continues throughout the healing journey, including post-burn scar management. This means undisturbed wound healing, improved cost-effectiveness, and a better patient experience1-5. It’s what we call the “Power of Gentle ."

“Nurses play a crucial role in the care of patients with burn injuries, and we are proud to offer them a powerful approach to burn care - Power of Gentle,” said Sheila Mays, Mölnlycke's Director of Professional Education. “By using Mölnlycke’s advanced wound care products, nurses can provide effective care, but also minimize pain during dressing changes and promote gentle healing6.”

At the 2024 annual meeting of the ABA, Mölnlycke will be a diamond sponsor and an exhibitor. During ABA, doctors, nurses, plastic surgeons, and other medical professionals specializing in burns will have the opportunity to experience Mölnlycke products and discover the gentle and effective care that Mölnlycke's products provide for burns. Attendees will see a wide range of the company's products for burn wound care, including its Mepilex Ag, Mepilex Transfer Ag, and Mepitel Ag. On April 10^th, the second day of the ABA annual meeting, Mölnlycke will sponsor a dinner symposium, where Dr. Paul M. Glat MD, FACS and Lindsay Burnett, BScN, MN, NP and will discuss how they treat burns, including their experience in using Mepilex Ag product.

In addition to hearing more from Dr. Glat and Lindsay Burnett about “the power of gentle,” in the dinner symposium, attendees will have the opportunity to speak directly with Mölnlycke representatives and learn more about the company's commitment to advancing wound care for both burns. "Our products have been shown to make a significant difference in the patient experience for those with burn injuries. We look forward to sharing our knowledge and expertise with attendees at the ABA annual meeting and bringing recognition to how “the power of gentle” can improve burn care for clinicians and patients," stated Sheila Mays, Mölnlycke's Director of Professional Education.

About Mölnlycke:

Mölnlycke is a world-leading medical products and solutions company. Our purpose is to advance performance in healthcare across the world, ensuring healthcare professionals have what they need to achieve the best clinical, patient, and financial outcomes. Learn more about The Power of Gentle and how Mölnlycke supports the patient by visiting [Mölnlycke's Website]

Mölnlycke Health Care
5445 Triangle Parkway, Suite 400
Peachtree Corners, GA 30092

REFERENCES

1. Gee Kee EL, Kimble RM, Cuttle L, Khan A, Stockton KA. Randomized controlled trial of three burns dressings for partial thickness burns in children. Burns 2015, 41(5):946-955.
2. Silverstein P, Heimbach D, Meites H et al. An open, parallel, randomized, comparative, multicenter study to evaluate the cost-effectiveness, performance, tolerance, and safety of a silver containing soft silicone foam dressing (intervention) vs silver sulfadiazine cream. J Burn Care Res 2011, 32(6): 617-626.
3. Gee Kee EL, Stockton K, Kimble RM et al. Cost-effectiveness of silver dressings for paediatric partial thickness burns: An economic evaluation from a randomized controlled trial. Burns 2017, 43(4): 724-732.
4. Aggarwala S, Harish V, Roberts S et al. Treatment of partial thickness burns: a prospective, randomised controlled trial comparing Biobrane, Acticoat, Mepilex Ag and Aquacel Ag. J Burn Care Res 2020, 42(5): 934-43.
5. Tang H, Lv G, Fu J et al. An open, parallel, randomized, comparative, multicenter investigation evaluating the efficacy and tolerability of Mepilex Ag versus silver sulfadiazine in the treatment of deep partial-thickness burn injuries. J Trauma Acute Care Surg 2015, 78(5): 1000-10071.
6. Upton D, Solowiej K. Pain and stress as contributors to delayed wound healing. Wound Practice and Research 2010, Vol. 18(3).